» Articles » PMID: 19117056

The Karyopherin Proteins, Crm1 and Karyopherin Beta1, Are Overexpressed in Cervical Cancer and Are Critical for Cancer Cell Survival and Proliferation

Overview
Journal Int J Cancer
Specialty Oncology
Date 2009 Jan 1
PMID 19117056
Citations 138
Authors
Affiliations
Soon will be listed here.
Abstract

The Karyopherin proteins are involved in nucleo-cytoplasmic trafficking and are critical for protein and RNA subcellular localization. Recent studies suggest they are important in nuclear envelope component assembly, mitosis and replication. Since these are all critical cellular functions, alterations in the expression of the Karyopherins may have an impact on the biology of cancer cells. In this study, we examined the expression of the Karyopherins, Crm1, Karyopherin beta1 (Kpnbeta1) and Karyopherin alpha2 (Kpnalpha2), in cervical tissue and cell lines. The functional significance of these proteins to cancer cells was investigated using individual siRNAs to inhibit their expression. Microarrays, quantitative RT-PCR and immunofluorescence revealed significantly higher expression of Crm1, Kpnbeta1 and Kpnalpha2 in cervical cancer compared to normal tissue. Expression levels were similarly elevated in cervical cancer cell lines compared to normal cells, and in transformed epithelial and fibroblast cells. Inhibition of Crm1 and Kpnbeta1 in cancer cells significantly reduced cell proliferation, while Kpnalpha2 inhibition had no effect. Noncancer cells were unaffected by the inhibition of Crm1 and Kpnbeta1. The reduction in proliferation of cancer cells was associated with an increase in a subG1 population by cell cycle analysis and Caspase-3/7 assays revealed increased apoptosis. Crm1 and Kpnbeta1 siRNA-induced apoptosis was accompanied by an increase in the levels of growth inhibitory proteins, p53, p27, p21 and p18. Our results demonstrate that Crm1, Kpnbeta1 and Kpnalpha2 are overexpressed in cervical cancer and that inhibiting the expression of Crm1 and Kpnbeta1, not Kpnalpha2, induces cancer cell death, making Crm1 and Kpnbeta1 promising candidates as both biomarkers and potential anticancer therapeutic targets.

Citing Articles

Targeting KPNB1 suppresses AML cells by inhibiting HMGB2 nuclear import.

Xie Y, Zhao R, Zheng Y, Li Y, Wu F, Lei Y Oncogene. 2025; .

PMID: 40082556 DOI: 10.1038/s41388-025-03340-0.


Targeting of nucleo‑cytoplasmic transport factor exportin 1 in malignancy (Review).

Ozdas S, Canatar I Med Int (Lond). 2024; 2(1):2.

PMID: 38938904 PMC: 11208992. DOI: 10.3892/mi.2021.27.


Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality?.

Andres C, Perez de la Lastra J, Munguira E, Juan C, Perez-Lebena E Int J Mol Sci. 2024; 25(11).

PMID: 38892287 PMC: 11172677. DOI: 10.3390/ijms25116099.


Analysis of the effects of importin α1 on the nuclear translocation of IL-1α in HeLa cells.

Yamada A, Wake K, Imaoka S, Motoyoshi M, Yamamoto T, Asano M Sci Rep. 2024; 14(1):1322.

PMID: 38225348 PMC: 10789739. DOI: 10.1038/s41598-024-51521-w.


Treatment of multiple myeloma with selinexor: a review.

Huang Q, Zhao R, Xu L, Hao X, Tao S Ther Adv Hematol. 2024; 15:20406207231219442.

PMID: 38186637 PMC: 10771077. DOI: 10.1177/20406207231219442.


References
1.
Stewart D, Ghosh A, Matlashewski G . Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53. J Virol. 2005; 79(14):8773-83. PMC: 1168768. DOI: 10.1128/JVI.79.14.8773-8783.2005. View

2.
Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso S . Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006; 98(7):472-82. DOI: 10.1093/jnci/djj103. View

3.
Kau T, Silver P . Nuclear transport as a target for cell growth. Drug Discov Today. 2003; 8(2):78-85. DOI: 10.1016/s1359-6446(02)02562-x. View

4.
Wrede D, Tidy J, Crook T, Lane D, Vousden K . Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines. Mol Carcinog. 1991; 4(3):171-5. DOI: 10.1002/mc.2940040302. View

5.
Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner E, Wolff B . Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A. 1999; 96(16):9112-7. PMC: 17741. DOI: 10.1073/pnas.96.16.9112. View